NO20091735L - Radiofluorering - Google Patents

Radiofluorering

Info

Publication number
NO20091735L
NO20091735L NO20091735A NO20091735A NO20091735L NO 20091735 L NO20091735 L NO 20091735L NO 20091735 A NO20091735 A NO 20091735A NO 20091735 A NO20091735 A NO 20091735A NO 20091735 L NO20091735 L NO 20091735L
Authority
NO
Norway
Prior art keywords
compounds
radio fluorination
labeled
fluorination
radio
Prior art date
Application number
NO20091735A
Other languages
English (en)
Norwegian (no)
Inventor
Ulrich Klar
Ananth Srinivasan
Timo Stellfeld
Simon Ametamey
Lutz Lehmann
Ulrike Rohn
Aileen Hohne
Linjing Mu
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06076823A external-priority patent/EP1908472A1/de
Priority claimed from EP06076869A external-priority patent/EP1911452A1/de
Priority claimed from EP07090043A external-priority patent/EP1970064A1/de
Priority claimed from EP07090079A external-priority patent/EP1985624A3/de
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of NO20091735L publication Critical patent/NO20091735L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0834—Compounds having one or more O-Si linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0896—Compounds with a Si-H linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/12—Organo silicon halides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C07K7/086—Bombesin; Related peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Nuclear Medicine (AREA)
NO20091735A 2006-10-02 2009-04-30 Radiofluorering NO20091735L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP06076823A EP1908472A1 (de) 2006-10-02 2006-10-02 Silicon-Derivate zur PET-Abbildung
EP06076869A EP1911452A1 (de) 2006-10-11 2006-10-11 Silicon-Derivate zur PET-Abbildung
EP07090043A EP1970064A1 (de) 2007-03-12 2007-03-12 Siliciumderivate zur PET-Abbildung
EP07090079A EP1985624A3 (de) 2007-04-23 2007-04-23 Einschrittiges Verfahren zur Radiofluorierung von biologisch aktiven Verbindungen oder Biomolekülen
PCT/EP2007/008044 WO2008040441A2 (en) 2006-10-02 2007-09-07 Silicon derivatives for pet imaging

Publications (1)

Publication Number Publication Date
NO20091735L true NO20091735L (no) 2009-06-30

Family

ID=39030886

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091735A NO20091735L (no) 2006-10-02 2009-04-30 Radiofluorering

Country Status (21)

Country Link
US (1) US20090035215A1 (de)
EP (1) EP2074135A2 (de)
JP (1) JP2010505776A (de)
KR (1) KR20090085599A (de)
AR (1) AR062795A1 (de)
AU (1) AU2007304508A1 (de)
BR (1) BRPI0719956A2 (de)
CA (1) CA2664700A1 (de)
CO (1) CO6180444A2 (de)
CR (1) CR10703A (de)
IL (1) IL197817A0 (de)
MA (1) MA30824B1 (de)
MX (1) MX2009003617A (de)
NO (1) NO20091735L (de)
PA (1) PA8747601A1 (de)
PE (1) PE20081173A1 (de)
SV (1) SV2009003205A (de)
TN (1) TN2009000100A1 (de)
TW (1) TW200820988A (de)
UY (1) UY30596A1 (de)
WO (1) WO2008040441A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2627486T3 (es) 2010-01-25 2017-07-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Biomoléculas sililadas
JP5717138B2 (ja) * 2011-05-23 2015-05-13 独立行政法人産業技術総合研究所 タンパク質固定化表面修飾材料
WO2014196540A1 (ja) * 2013-06-06 2014-12-11 日産化学工業株式会社 アルコキシシラン化合物、液晶配向剤、液晶配向膜及び液晶表示素子
US10800797B2 (en) 2015-05-26 2020-10-13 California Institute Of Technology Heteroaromatic silicon-fluoride-acceptors useful for 18F labeling of molecules and biomolecules, and methods of preparing same
WO2019055825A1 (en) 2017-09-15 2019-03-21 The Regents Of The University Of California INHIBITION OF AMINOACYLASE 3 (AA3) IN THE TREATMENT OF CANCER
WO2021226076A1 (en) * 2020-05-04 2021-11-11 The Research Foundation For The State University Of New York Positron imaging tomography imaging agent composition and method for detection of bacterial infection
EP4218831A4 (de) * 2020-09-28 2024-03-06 National Institutes for Quantum Science and Technology Verfahren zur herstellung einer radioaktiv markierten substanz, vorrichtung zur herstellung einer radioaktiv markierten substanz und verfahren zur verdampfung und konzentration von radioaktivem metallnuklid

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084555A (en) * 1989-08-21 1992-01-28 The Administrators Of The Tulane Educational Fund An octapeptide bombesin analog
US5732578A (en) * 1995-02-24 1998-03-31 Hyundai Metal Co., Ltd. Device for maintaining the horizontality of a door lock lever
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
US6639076B1 (en) * 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
JP2003502314A (ja) * 1999-06-14 2003-01-21 イーライ・リリー・アンド・カンパニー 化合物
AU2002228725A1 (en) * 2000-11-30 2002-06-11 Advanced Research And Technology Institute, Inc. Nucleophilic approach for preparing radiolabeled imaging agents and associated compounds
GB0206750D0 (en) * 2002-03-22 2002-05-01 Amersham Plc Radiofluorination methods
US7342095B2 (en) * 2003-02-20 2008-03-11 University Of South Florida Peptidomimetic inhibitors of STAT activity and uses thereof
GB0305704D0 (en) * 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods
EP1723161A4 (de) * 2004-02-13 2010-04-28 Univ British Columbia Radioaktiv markierte verbindungen und zusammensetzungen, vorstufen davon und verfahren zu deren herstellung
US20080029548A1 (en) * 2006-05-05 2008-02-07 Ann De Wree Fabric treatment dispensing package

Also Published As

Publication number Publication date
EP2074135A2 (de) 2009-07-01
CR10703A (es) 2009-06-25
PE20081173A1 (es) 2008-11-06
KR20090085599A (ko) 2009-08-07
TW200820988A (en) 2008-05-16
IL197817A0 (en) 2009-12-24
JP2010505776A (ja) 2010-02-25
TN2009000100A1 (en) 2010-08-19
UY30596A1 (es) 2008-05-02
CA2664700A1 (en) 2008-04-10
SV2009003205A (es) 2009-10-19
MA30824B1 (fr) 2009-10-01
CO6180444A2 (es) 2010-07-19
WO2008040441A2 (en) 2008-04-10
AR062795A1 (es) 2008-12-03
WO2008040441A3 (en) 2009-01-08
US20090035215A1 (en) 2009-02-05
AU2007304508A1 (en) 2008-04-10
MX2009003617A (es) 2009-04-22
PA8747601A1 (es) 2009-08-26
BRPI0719956A2 (pt) 2014-04-29
AU2007304508A8 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
NO20091428L (no) Forbindelser og metoder for 18F-merkede midler
NO20091735L (no) Radiofluorering
NO20083598L (no) Karbosykliske og heterosykliske arylsulfoner som inhibitorer av gamma-sekretase
UA103319C2 (en) Thiazole- and oxazole-benzene sulfonamide compounds
EA201100301A1 (ru) Daa-пиридин в качестве лиганда периферического бензодиазепинового рецептора для диагностической визуализации и фармацевтического лечения
NO20084278L (no) Bezothiazol derivatives as beta2 adrenoreceptor agonists
CR10694A (es) Compuestos antagonistas del receptor de glucagon, composiciones que contienen dichos compuestos y procedimientos de uso
ATE555105T1 (de) Heterocyclische fxr-bindende verbindungen
TN2011000279A1 (en) Novel pyrazole -4-n-alkoxycarboxamides as microbiocides
NO20055688L (no) Organiske forbindelser
FR2911866B1 (fr) Solide cristalise izm-1 et son procede de preparation.
NO20083153L (no) Kjemiske forbindelser
ATE536864T1 (de) Metoprololsuccinat tabletten mit verlängerter freisetzung und verfahren für deren herstellung
EP1917542A4 (de) Verfahren zur tomographischen inversion durch matrixtransformation
ATE459620T1 (de) Benzimidazolthiophenverbindungen als plk- modulatoren
DE602006008639D1 (de) Automatisches radioaktives markierungsverafhren
WO2009127718A3 (en) Novel microbiocides
FR2940266B1 (fr) Solide cristallise im-20 et son procede de preparation
BRPI1008191A8 (pt) Composto, processo para preparação de monoidrato de l-glicose, composição, método para limpeza de cólon, kit de limpeza de cólon
DE112006000984A5 (de) Verfahren zur Herstellung von 2,5-substituierten Tetrahydropyran-Derivaten durch reduktive Eliminierung des entsprechenden 4-Halogen-Derivats
WO2006080043A3 (en) Organic compounds useful for the treatment of alzheimer's disease, their use and method of preparation
NO20092813L (no) Radiomerking via fluorinering av aziridiner
FR2923476B1 (fr) Solide cristalise im-17 et son procede de preparation
NZ610736A (en) Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system
CL2008001912A1 (es) Procedimiento de preparacion de compuestos derivados de bencimidazol tienilamina, utiles como agentes inhibidores del agente de intercambio sodio/proton del tipo 3; compuestos intermediarios.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application